CASP3 and neoplasm: The combination of oxaliplatin and XL413 significantly inhibited xenograft tumor growth (Figure 6G), which showed remarkably decreased Ki‐67 and increased cleaved‐caspase 3 in IHC analysis (Figure 6H).